- Home
- IDAI vs AEON Comparison
IDAI vs AEON Comparison
Compare IDAI & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- AEON
- Stock Information
- Founded
- IDAI 2016
- AEON N/A
- Country
- IDAI United States
- AEON United States
- Employees
- IDAI N/A
- AEON N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- IDAI Technology
- AEON Health Care
- Exchange
- IDAI Nasdaq
- AEON Nasdaq
- Market Cap
- IDAI 7.7M
- AEON 8.0M
- IPO Year
- IDAI N/A
- AEON N/A
- Fundamental
- Price
- IDAI $3.64
- AEON N/A
- Analyst Decision
- IDAI Strong Buy
- AEON Strong Buy
- Analyst Count
- IDAI 1
- AEON 1
- Target Price
- IDAI $12.00
- AEON $7.20
- AVG Volume (30 Days)
- IDAI 1.7M
- AEON 270.7K
- Earning Date
- IDAI 11-14-2025
- AEON 11-12-2025
- Dividend Yield
- IDAI N/A
- AEON N/A
- EPS Growth
- IDAI N/A
- AEON N/A
- EPS
- IDAI N/A
- AEON N/A
- Revenue
- IDAI $3,366,415.00
- AEON N/A
- Revenue This Year
- IDAI $25.13
- AEON N/A
- Revenue Next Year
- IDAI $164.45
- AEON N/A
- P/E Ratio
- IDAI N/A
- AEON N/A
- Revenue Growth
- IDAI N/A
- AEON N/A
- 52 Week Low
- IDAI $1.43
- AEON $0.38
- 52 Week High
- IDAI $18.75
- AEON $83.52
- Technical
- Relative Strength Index (RSI)
- IDAI 64.41
- AEON 71.00
- Support Level
- IDAI $3.50
- AEON $0.90
- Resistance Level
- IDAI $4.07
- AEON $1.22
- Average True Range (ATR)
- IDAI 0.29
- AEON 0.09
- MACD
- IDAI 0.05
- AEON 0.03
- Stochastic Oscillator
- IDAI 66.35
- AEON 75.00
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.